Clinical Trial Detail

NCT ID NCT02857270
Title A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

pancreatic ductal adenocarcinoma

Advanced Solid Tumor

melanoma

colorectal cancer

lung non-small cell carcinoma

Therapies

LY3214996

Gemcitabine + LY3214996 + Nab-paclitaxel

LY3214996 + Midazolam

Abemaciclib + LY3214996

Age Groups: adult senior

Additional content available in CKB BOOST